ProQR was born from the dream to beat cystic fibrosis in just one child. Now ProQR has one goal. Use groundbreaking science to develop medicines that will transform the lives of patients with severe genetic disorders and their loved ones.
Play the movie to learn more about
what drives us at ProQR.
We are ProQR
Leber’s Congenital Amaurosis
Leber's congenital amaurosis Type 10 (LCA 10) is a genetic eye disorder and the leading genetic cause of childhood blindness. We are developing a potentially life changing therapy for patients that suffer from LCA 10 due to the p.Cys998X mutation in the CEP290 gene.
Read more about QR-110 for Leber's congenital amaurosis Type 10
Cystic fibrosis is a progressive disease affecting the lung and other vital organs, leading to a limited life expectancy. We are developing drugs to help patients that suffer from different forms of cystic fibrosis. Our first candidate medicine, called QR-010, for the F508del mutations showed very encouraging results in the first two clinical trials. For other forms of CF we have initiated discovery projects to find new medicine candidates.
Read more about QR-010 for cystic fibrosis and clinical trials
Dystrophic Epidermolysis Bullosa
Dystrophic epidermolysis bullosa (DEB) is a severe genetic skin disease. Children with DEB are often called 'Butterfly children' as their skin is as fragile as the wings of a butterfly. We are developing several programs for different mutations causing DEB including QR-313 for approximately 2,000 patients that have DEB due to mutations in exon 73 of the COL7A1 gene.
Read more about QR-313 for dystrophic epidermolysis bullosa
Usher syndrome type 2
Usher syndrome is the leading cause of combined deafness and blindness. We are developing two drug candidates for different mutations causing Usher syndrome type 2 including lead program QR-421a for approximately 12,000 patients with a mutation in exon 13 of the USH2A gene and QR-411 for approximately 1,000 patients with a the c.7595-2144A>G mutation in the USH2A gene. Read more about QR-421a and QR-411 for Usher syndrome type 2
Axiomer® RNA editing technology
At the ProQR labs a novel technology called Axiomer was invented that has the potential to treat a large number of diseases that are currently untreatable. Axiomer is a novel way to correct RNA in the cells in patients and target mutations that cannot be treated with other technologies. Our scientists are working hard to make the promise of this technology for patients come true.
Read more about Axiomer
Spin out: Amylon Therapeutics
In September 2017 ProQR created a new company that is focused on the development of drugs for genetic brain diseases. Amylon Therapeutics is building a team of experts in brain diseases and has raised a financing round with private and institutional shareholders. ProQR retains a majority ownership stake in Amylon.
Read more about the spin out in the press release
Visit the Amylon website